Drugs / Emblica Officinalis
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT03633630 | Apr 2019 → Oct 2021 | metabolic syndrome X | University of Guadalajara | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Emblica Officinalis | “Amla (Emblica Officinalis)” NCT03633630 ↗ |
| Known as | Amla | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03633630 ↗ |
| Route | Oral | “receive Amla (500mg) or homologated placebo orally twice daily” NCT03633630 ↗ |